Literature DB >> 1477653

High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel.

Y Chaiter1, B Brenner, E Aghai, I Tatarsky.   

Abstract

We have analysed epidemiological parameters in 339 patients with myeloproliferative disorders (MPD) diagnosed in northern Israel between 1975 and 1989 as having polycythemia vera (191 patients), agnogenic myeloid metaplasia (AMM) (113) and essential thrombocythemia (ET) (36). Mean average annual incidence was 11.4 per 1 million residents for polycythemia vera, 6.5 for AMM and 2.1 for ET. For all three diseases the average annual incidence increased with age and was 10 times higher in patients over 65 years compared to those less under the age of 45 years. Four percent of all patients had relatives with MPD. Incidence of MPD in Jews was 10 fold higher than expected compared to Arabs and this difference was noted for all 3 diseases. The incidence in Ashkenazi Jews originating from eastern and central Europe, was 10 and 20 folds higher than in Sephardic Jews and Arabs respectively. Mean age at diagnosis of MPD in Arabs and Sephardic Jews was lower than in Ashkenazi Jews (52 and 56 years compared to 64 years P < 0.05). Likewise, mean age at diagnosis was lower in the 11.5% of MPD patients with prior exposure to biological or chemical hazards compared to unexposed individuals (58 years versus 63 years, P < 0.02). These data demonstrate a cluster of MPD in Ashkenazi Jews in northern Israel and emphasize the importance of genetic predisposition possibly interacting with acquired factors in the pathogenesis of these disorders.

Entities:  

Mesh:

Year:  1992        PMID: 1477653     DOI: 10.3109/10428199209053630

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  12 in total

1.  Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study.

Authors:  François Girodon; Gilles Bonicelli; Céline Schaeffer; Morgane Mounier; Serge Carillo; Ingrid Lafon; Paule Marie Carli; Inès Janoray; Emmanuelle Ferrant; Marc Maynadié
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

2.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

3.  Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.

Authors:  Alexis D Leal; Carrie A Thompson; Alice H Wang; Robert A Vierkant; Thomas M Habermann; Julie A Ross; Ruben A Mesa; Beth A Virnig; James R Cerhan
Journal:  Int J Cancer       Date:  2013-10-15       Impact factor: 7.396

Review 4.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

5.  A cluster of vitreoretinal lymphoma in New York with possible link to the Chernobyl nuclear disaster.

Authors:  Sanford Kempin; Paul T Finger; Robert Peter Gale; John Rescigno; Jeffrey Rubin; Walter Choi; Rebecca Fisher; Alexander Aizman; Ilona Genis; Stephen C Malamud; Roxana Moslehi
Journal:  Leuk Lymphoma       Date:  2017-11-22

Review 6.  From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

7.  Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.

Authors:  Alen Ostojic; Radovan Vrhovac; Srdan Verstovsek
Journal:  Future Oncol       Date:  2011-09       Impact factor: 3.404

Review 8.  Polycythaemia vera and essential thrombocythaemia in the elderly.

Authors:  P J van Genderen; M M Troost
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

9.  Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study.

Authors:  Nikolai A Podoltsev; Xiaoyi Wang; Rong Wang; Jonathan N Hofmann; Linda M Liao; Amer M Zeidan; Ruben Mesa; Xiaomei Ma
Journal:  Int J Cancer       Date:  2020-01-29       Impact factor: 7.396

10.  Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort.

Authors:  Nikolai A Podoltsev; Xiaoyi Wang; Rong Wang; Jonathan N Hofmann; Linda M Liao; Amer M Zeidan; Ruben A Mesa; Xiaomei Ma
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-08-31       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.